FIGURE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

The left panels show the number of CD4⁺ T cells (top) and CD8⁺ T cells (bottom) over time, separated by responders (CR+PR, solid circles) versus nonresponders (SD+PD, open circles). The right panels show the percentage of effector T cells over time, with CD4⁺IFNγ⁺ T cells (top) and CD8⁺IFNγ⁺ T cells (bottom). Plot is mean value and error bars show ± 1 SE. The * shows the statistically significant increase in CD4⁺IFNγ⁺ T cells in responders versus nonresponders (P = 0.047). X-axis is assessment at baseline (bsl), after cycle 3 (C3), and after cycle 6 (C6).